Drug Trial Radar · NCT04660344
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
761
Actual
Start
May 3, 2021
Primary completion
Jun 15, 2025
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Natera, Inc.
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy.
Conditions
- Muscle-invasive Bladder Cancer
Interventions
AtezolizumabDrug
ctDNA positive participants will receive 1680 mg IV, every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
PlaceboOther
ctDNA positive participants will receive placebo IV, Q4W on Day 1 of each 28-day cycle
SignateraDevice
Signatera will be used to evaluate whether ctDNA is detected during serial monitoring of peripheral blood samples for participants enrolled in surveillance. Participants with a ctDNA positive result will be screened for inclusion in the treatment phase. Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- INV-assessed Disease-free Survival (DFS)Time frame: From randomization to the first occurrence of a DFS event (Up to 48.2 months)
Locations
140 sites in 23 countries. Site status is shown where the registry gives one.
Cancer Care Centers of Brevard
Rockledge, Florida
Cleveland Clinic
Cleveland, Ohio
AHN Cancer Institute ? Allegheny General Hospital
Pittsburgh, Pennsylvania
Centro Medico Austral
Buenos Aires, Argentina
Instituto Alexander Fleming
Buenos Aires, Argentina
AZ KLINA
Brasschaat, Belgium
UZ Gent
Ghent, Belgium
Oncocentro Serviços Medicos E Hospitalares Ltda
Fortaleza, Ceará, Brazil
CETUS Hospital Dia Oncologia
Belo Horizonte, Minas Gerais, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
*X*Fundação Pio XII Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Hospital Alemao Oswaldo Cruz
São Paulo, São Paulo, Brazil
Friendship Hospital, Capital Medical University
Beijing, China
the First Hospital of Jilin University
Changchun, China
Hu Nan Provincial Cancer Hospital
Changsha, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Jiangsu Cancer Hospital
Nanjing, China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, China
Zhongshan Hospital Fudan University
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Tianjin Cancer Hospital
Tianjin, China
Yantai Yu Huangding Hospital
Yantai, China
Clinica del Country
Bogotá, Colombia
Instituto Cancerología Medellin
Medellín, Colombia
Oncomedica S.A.
Montería, Colombia
Fakultni nemocnice Olomouc
Olomouc, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Fakultni Thomayerova nemocnice
Praha 4 - Krc, Czechia
ICO Paul Papin
Angers, France
Institut Sainte Catherine
Avignon, France
Hopital Saint Andre
Bordeaux, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Léon Bérard
Lyon, France
Centre D'Oncologie de Gentilly
Nancy, France
Institut Mutualiste Montsouris
Paris, France
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.